Department of Cancer Research

Medicine & Life Sciences

1. Glioblastoma 100%
2. Neoplasms 85%
3. Glioma 51%
4. Proteomics 42%
5. Autophagy 39%
6. Natural Killer Cells 37%
7. Proteins 36%
8. Tumor Microenvironment 31%
9. B-Cell Chronic Lymphocytic Leukemia 28%
10. Genes 25%
11. Brain Neoplasms 24%
12. Immunotherapy 24%
13. Hypoxia 23%
14. Therapeutics 22%
15. Actin Cytoskeleton 22%
16. Actins 21%
17. Brain 21%
18. Melanoma 21%
19. Heterografts 21%
20. Growth 20%
21. Microglia 18%
22. Biomarkers 17%
23. Peptides 16%
24. Phenotype 16%
25. Mass Spectrometry 15%
26. Neoplasm Metastasis 15%
27. Abies 15%
28. T-Lymphocytes 15%
29. Macrophages 14%
30. Breast Neoplasms 14%
31. MicroRNAs 14%
32. In Vitro Techniques 14%
33. Mutation 13%
34. Cell Line 13%
35. Survival 12%
36. Stem Cells 11%
37. Immunity 11%
38. Immunological Synapses 11%
39. Proteome 11%
40. Gene Expression 10%
41. itaconic acid 10%
42. formic acid 10%
43. plastin 10%
44. Pharmaceutical Preparations 10%
45. Temozolomide 10%
46. Transcriptome 9%
47. Parkinson Disease 9%
48. Isocitrate Dehydrogenase 9%
49. Inflammation 9%
50. Neoplastic Stem Cells 9%
51. Methylation 9%
52. Epigenomics 9%
53. Oncolytic Viruses 9%
54. Datasets 9%
55. Colorectal Neoplasms 9%
56. Lung Neoplasms 8%
57. Leukemia 8%
58. Arabidopsis 8%
59. DNA Methylation 8%
60. Epithelial-Mesenchymal Transition 8%
61. Cytokines 8%
62. Tumor Escape 8%
63. Long Noncoding RNA 8%
64. H-1 parvovirus 8%
65. Blood-Brain Barrier 8%
66. Ligands 7%
67. DNA Repair 7%
68. Apoptosis 7%
69. Cytotoxic T-Lymphocytes 7%
70. Cell Movement 7%
71. Up-Regulation 7%
72. Transcription Factors 7%
73. Protein Isoforms 7%
74. Triterpenes 7%
75. Cell Death 7%
76. Astrocytes 7%
77. Ions 7%
78. Phosphorylation 6%
79. Extracellular Vesicles 6%
80. Organoids 6%
81. Gene Expression Profiling 6%
82. ErbB Receptors 6%
83. Sesquiterpenes 6%
84. RNA Sequence Analysis 6%
85. Biopsy 6%
86. Drug Therapy 6%
87. Animal Models 6%
88. Cell Plasticity 6%
89. RNA 6%
90. Genome 6%
91. Myeloid-Derived Suppressor Cells 6%
92. Central Nervous System 6%
93. Histone Deacetylase Inhibitors 6%
94. Workflow 6%
95. DNA Damage 5%
96. B-Lymphocytes 5%
97. Phosphotransferases 5%
98. Histones 5%
99. Multiple Myeloma 5%
100. chondroitin sulfate proteoglycan 4 5%